Patent intelligence · US
US 10000746
LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
Patent details — US 10000746
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 19, 2018
- Expiration
- Jun 14, 2038
- Applicant
- PRECISION GENOME ENGINEERING, INC.
- Claims
- 21
- CPC classes
- A61K, A61K38/465, A61K48/00, A61P
Quick answer
US 10000746 (LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof) is held by PRECISION GENOME ENGINEERING, INC.. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION GENOME ENGINEERING, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/465, A61K48/00, A61P, A61P35/00
More from PRECISION GENOME ENGINEERING, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 10000746?
US 10000746 (LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof) is held by PRECISION GENOME ENGINEERING, INC.. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10000746?
PRECISION GENOME ENGINEERING, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 10000746 expire?
Our index shows an expiration date of Jun 14, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.